T cells

[Minerva Biotechnologies] Minerva Biotechnologies Corporation announced that its trial of huMNC2-CAR44 T cells has now opened at City of Hope, Duarte, California. This is a first-in-human trial targeting the tumor-associated form of MUC1, called MUC1*, the transmembrane cleavage product that is a growth factor receptor that drives growth of an estimated 93% of breast cancers.

[Proceedings of the National Academy of Sciences of the United States of America] The authors found that multiclonal Tregs presented in tumor tissues predominantly expressed the chemokine receptor CCR8.

[Nature Cell Biology] The authors reported that cancer cells with aberrant expression of glutamate decarboxylase 1 rewired glutamine metabolism for the synthesis of γ-aminobutyric acid (GABA)—a prominent neurotransmitter—in non-nervous tissues.

[JCI Insight] Scientists examined the spatial localization, phenotype, and function of CD8+ T cells in the human duodenal tissue from people living with HIV and healthy controls.

[Science Advances] Investigators found that T cell–specific deletion of nuclear helicase Dhx9 led to impaired CD8+ T cell survival, effector differentiation, and viral clearance.

[Arteriosclerosis Thrombosis and Vascular Biology] Scientists discuss key findings from the latest research that give insight into the mechanisms by which clonal expansion of vascular cells contributes to disease pathology.